Table 3.

CTCAE v4.0 treatment-related Grade 1–2 and all Grade 3–4 adverse events, Unselected Cohort

Adverse Event	Grade 1–2 (#Patients)	Grade 3–4 (#Events / #Patients [#Treatment-Related])
Hyperglycemia	13	6/2 (5)
Fatigue	12	0
Weight loss	8	0
Mucositis oral	7	0
Diarrhea	6	0
Alanine aminotransferase increased	5	0
Nausea	5	0
Rash maculo-papular	5	1/1 (1)
Aspartate aminotransferase increased	4	1/1 (0)
Depression	3	1/1 (1)
Dry Skin	4	0
Hyperkalemia	4	0
Photosensitivity	4	0
Anorexia	3	0
Anxiety	3	0
Dyspepsia	3	0
Cholesterol high	2	0
Creatinine increased	2	0
Flatulence	2	0
Hypophosphatemia	2	2/1 (0)
Pruritus	2	2/1 (0)
Rash acneiform	2	0
Skin & subcutaneous tissue disorders Other;
Erythema	2	1/1 (1)
Rosacea	1	0
Vomiting	2	0
Abdominal pain	1	1/1 (0)
Alopecia	1	0
Alkaline phosphatase increased	1	0
Constipation	1	0
Cough	1	0
Endocrine disorders – Other; SIADH	1	0
Gastrointestinal disorders – other; Dry heaves	1	0
Hypertriglyceridemia	1	0
Hypocalcemia	1	0
Hypokalemia	1	2/1 (2)
Hypernatremia	1	0
Hyponatremia	1	1/1 (0)
Lymphocyte count decreased	1	19/2 (0)
Muscle weakness	1	0
Platelet count decreased	1	1/1 (0)
White blood cell decreased	1	1/1 (0)
Anemia	0	5/1 (0)
Hyperuricemia	0	1/1 (0)
Infection	0	1/1 (0)
Small intestinal obstruction	0	1/1 (0)
Syncope	0	2/2 (0)
Thromboembolic event	0	1/1 (0)